Literature DB >> 7675441

Alternate splicing produces a novel cyclin D1 transcript.

D C Betticher1, N Thatcher, H J Altermatt, P Hoban, W D Ryder, J Heighway.   

Abstract

Using Northern blotting and PCR analysis of cDNA derived from a range of cell lines and tissues, alternate splicing of the cyclin D1 gene (CCND1) mRNA has been demonstrated. The variant transcript shows no splicing at the downstream exon 4 boundary, encoding a protein with an altered carboxy-terminal domain. Investigation of mRNA extracted from mononuclear cells, lung tumour and normal tissue suggests that both transcripts are invariably expressed. However, splicing to produce the two forms of mRNA is modulated, in the heterozygote, by a frequent A/G polymorphism located within the splice donor region of exon 4. Preliminary analysis of patients with resectable non-small cell lung cancer suggests that genotype is associated with shortened event free survival and greater risk of local relapse.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675441

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  133 in total

Review 1.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Authors:  Vandana Gupta Abramson; Andrea B Troxel; Michael Feldman; Carolyn Mies; Yan Wang; Lauren Sherman; Sara McNally; Alan Diehl; Angela Demichele
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

3.  Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Authors:  Teresa Warchoł; Lukasz Kruszyna; Margarita Lianeri; Andrzej Roszak; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2010-08-03       Impact factor: 3.201

4.  CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis.

Authors:  Chunbo Tang; Zhanwei Wang; Jinhua Yu; Yunong Wu; Zhijun Zhu; Ning Chen
Journal:  Med Oncol       Date:  2010-05-05       Impact factor: 3.064

5.  CYP17 polymorphisms and prostate cancer outcomes.

Authors:  Jonathan L Wright; Erika M Kwon; Daniel W Lin; Suzanne Kolb; Joseph S Koopmeiners; Ziding Feng; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2010-07-01       Impact factor: 4.104

6.  Oligogenic combinations associated with breast cancer risk in women under 53 years of age.

Authors:  Christopher E Aston; David A Ralph; Dominique P Lalo; Sharmila Manjeshwar; Bobby A Gramling; Daniele C DeFreese; Amy D West; Dannielle E Branam; Linda F Thompson; Melissa A Craft; Debra S Mitchell; Craig D Shimasaki; John J Mulvihill; Eldon R Jupe
Journal:  Hum Genet       Date:  2004-12-21       Impact factor: 4.132

7.  Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.

Authors:  Pere Domingo; M Carmen Cabeza; Alain Pruvost; Ferran Torres; Juliana Salazar; M del Mar Gutierrez; M Gracia Mateo; Angels Fontanet; Irene Fernandez; Joan C Domingo; Francesc Villarroya; Francesc Vidal; Montserrat Baiget
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

8.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

9.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

10.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.